Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ERAS-801

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Erasca, Katmai Pharma

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR mutation	Glioblastoma	EGFR mutation	Glioblastoma	ERAS-801 Sensitive: B - Late Trials ERAS-801 Sensitive : B	ERAS-801 Sensitive: B - Late Trials ERAS-801 Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	ERAS-801 Sensitive: D – Preclinical ERAS-801 Sensitive : D	ERAS-801 Sensitive: D – Preclinical ERAS-801 Sensitive : D